Search hospitals > Quebec > MONTREAL
CHUM-Centre Hospitalier de l'Universite de Montreal
Claim this profileMONTREAL, Quebec H2X 3E4
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Prostatic Neoplasm
Conducts research for Parotid Gland Cancer
466 reported clinical trials
99 medical researchers
Summary
CHUM-Centre Hospitalier de l'Universite de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Prostatic Neoplasm, Parotid Gland Cancer and other specialties. CHUM-Centre Hospitalier de l'Universite de Montreal is involved with conducting 466 clinical trials across 648 conditions. There are 99 research doctors associated with this hospital, such as Daniel Von Renteln, MD, Diane Provencher, MD, FRCSC, Jean Raymond, MD, and Moishe Liberman, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Daniel Von Renteln, MDCentre Hospitalier de l'Université de Montréal (CHUM)2 years of reported clinical research
Studies Colorectal Cancer
Studies Polyps
14 reported clinical trials
19 drugs studied
Diane Provencher, MD, FRCSCCentre Hospitalier de l'Université de Montréal5 years of reported clinical research
Studies Ovarian Cancer
Studies Cancer
13 reported clinical trials
21 drugs studied
Jean Raymond, MDCentre Hospitalier de l'Université de Montréal14 years of reported clinical research
Studies Pararenal Aneurysms
Studies Intracranial Aneurysm
9 reported clinical trials
14 drugs studied
Moishe Liberman, MDCHUM3 years of reported clinical research
Studies Lung Cancer
Studies Pneumothorax
9 reported clinical trials
13 drugs studied
Clinical Trials running at CHUM-Centre Hospitalier de l'Universite de Montreal
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Cancer
Prostatic Neoplasm
Acute Kidney Injury
Squamous Cell Carcinoma
Brain Tumor
Cardiovascular Disease
Critical Illness
sac-TMT + Pembrolizumab
for Breast Cancer
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Recruiting2 awards Phase 35 criteria
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CHUM-Centre Hospitalier de l'Universite de Montreal?
Where is CHUM-Centre Hospitalier de l'Universite de Montreal located?
Who should I call to ask about financial aid or insurance network?
What insurance does CHUM-Centre Hospitalier de l'Universite de Montreal accept?
What awards or recognition has CHUM-Centre Hospitalier de l'Universite de Montreal received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.